Company profile for Immunity Pharma

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Immunity Pharma Ltd. (IPL) develops therapies for neuro-degenerative diseases with an initial focus on Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. While there is currently no cure for ALS, there is massive market potential for an ALS therapy. IPL’s lead drug, IPL344, originates from the research laboratory of Prof. Irun Cohen at the Weizmann Institute of Science, Israel.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Israel
Address
Address
28 Miron Street Mevasseret Zion Israel 90805
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/immunity-pharma-presents-new-data-supporting-the-efficacy-of-ipl344-in-als-302421482.html

PR NEWSWIRE
07 Apr 2025

https://www.prnewswire.com/news-releases/immunity-pharma-presents-new-data-supporting-the-efficacy-of-ipl344-in-als-302421483.html

PR NEWSWIRE
07 Apr 2025

https://www.prnewswire.com/news-releases/immunity-pharma-announces-positive-top-line-results-from-phase-2a-trial-with-ipl344-in-als-patients-302037139.html

PR NEWSWIRE
17 Jan 2024

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty